Expert guidelines, based on research evidence, to help clinicians provide care. They are produced by bodies such as the British HIV Association (BHIVA), the European AIDS Clinical Society (EACS) and the World Health Organization (WHO).

Treatment guidelines: latest news

Treatment guidelines resources

  • When to start treatment

    Until recently, doctors weren’t sure of the best time to start HIV treatment. In 2015 a large, well-conducted study demonstrated that there are advantages to starting treatment as...

    From: Booklets

    Information level Level 2
  • Starting HIV treatment

    It’s better to start HIV treatment sooner, rather than later.Treatment will reduce the risk of HIV transmission, prevent illnesses and extend your life.A range of different antiretroviral...

    From: Factsheets

    Information level Level 2
  • When to start treatment

    Until recently, doctors weren’t sure of the best time to start HIV treatment. However in 2015 a large, well-conducted study demonstrated that there are advantages to starting...

    From: Booklets

    Information level Level 2
  • HIV treatment as prevention

    This briefing paper, produced by NAM for HIV Prevention England, describes the scientific evidence for HIV treatment as prevention and considers its implications for the UK....

    From: HIV prevention briefing papers

Treatment guidelines features

Treatment guidelines news from aidsmap

More news

Treatment guidelines news selected from other sources

  • Australian doctors to tell HIV patients that 'undetectable=untransmissible'

    In what has been seen as major win for HIV advocates, the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) has released a guide to help doctors understand the ‘Undetectable=Untransmittable (U=U)’ campaign.

    24 July 2018 | Gay Star News
  • Dolutegravir: need to consider all pros and cons before switching in pregnancy

    A young pregnant woman who switched from dolutegravir (DTG)-based ART, in response to the neural tube defect safety signal, experienced viral rebound on her new regimen. She needed to be switched back to DTG to achieve re-suppression and prevent vertical transmission.

    11 July 2018 | HIV i-Base
  • All-access for blockbuster TB drug in South Africa

    The country made history on Monday when the health department announced that all drug-resistant tuberculosis (DR-TB) patients will be eligible to receive the new medicine, bedaquiline. “The Department of Health’s [DoH] commitment on bedaquiline is momentous globally and marks a new era of DR-TB management where we are really prioritising the patient,” Doctors Without Borders’ Dr Anja Reuters told Health-e News.

    19 June 2018 | Health-e
  • Starting HIV treatment at diagnosis slashes drop out, drug failure rates, China study finds

    Patients diagnosed with HIV who started antiretroviral treatment within 30 days had significantly lower rates of dropping out of treatment, and higher rates successful treatment, than those who started later, particularly those who started more than three months after their diagnosis, a study in China has found.

    04 June 2018 | Science Speaks
  • South Africa: Birth defects fears prompt warnings about new ARV

    Despite the public concern globally, very little has been said about the impact of the safety warning about dolutegravir on South Africa, the country with the largest HIV treatment programme in the world. The National Department of Health had already planned to introduce a dolutegravir-based first line regimen to replace the existing regimen, hoping to switch the majority of patients starting from last month.

    29 May 2018 | Health-e
  • HIV Care Gaps of Less Than 9 Months Do Not Worsen Patients

    Gaps in care of up to 9 months for patients with HIV do not worsen viral loads, a study involving more than 6000 HIV-infected individuals has found. Current guidelines specify that gaps in visits to primary care doctors should not exceed 6 months for clinically stable HIV patients with sustained viral suppression—even though longer lapses are common.

    16 May 2018 | MD Magazine
  • Phase 3 registrational data is not sufficient for roll-out of new ARVs in low- and middle-income countries

    Phase 3 randomised trials for drug approval in high-income countries do not provide sufficient evidence to support the widespread use of new antiretrovirals in low- and middle-income countries (LMICs), where the majority of people with HIV live. Key missing evidence is typically for pregnant women, people with HIV/TB coinfection and people who have not had resistance testing before starting ART.

    15 May 2018 | HIV i-Base
  • Computer Models Are Changing How We Craft HIV-AIDS Policies

    A computer modeling of AIDS-affected populations of sub-Saharan Africa has recently enabled the World Health Organization (WHO) to identify a cost-effective measure to address the increasing prevalence of drug-resistant HIV in the region.

    04 May 2018 | Healthcare Analytics News
  • Latest DHHS Guidelines for Initial HIV Therapy Now Include 5 Choices — But Really 2 Are Best

    With the important caveat that what follows represents my opinion and not that of these or any other guidelines, one could easily argue that there are really two primary choices here, not five.

    23 April 2018 | NEJM Journal Watch
  • India could shift from efavirenz to dolutegravir for HIV treatment – at no extra cost, new research suggests

    Researchers recommend dolutegravir (DTG)‐based antiretrovirals should become the first option for HIV treatment in India, following a study into DTG’s cost-effectiveness.

    13 April 2018 | Avert
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.